Background: Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs. Methods: The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants. Results: A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α (P
CITATION STYLE
Ganesh, R., Yadav, S., Hurt, R. T., Mueller, M. R., Aakre, C. A., Gilman, E. A., … Salonen, B. R. (2024). Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs. Journal of Primary Care and Community Health, 15. https://doi.org/10.1177/21501319241254751
Mendeley helps you to discover research relevant for your work.